Get the latest news on Black Swan Graphene stock with updates on market trends, financials, and analysis from Benzinga. Stay informed on BSWGD performance

Latest Black Swan Graphene Stock News | OTC:BSWGD | Benzinga

Black Swan Graphene Inc is focused on the large-scale production and commercialization of patented high-performance and low-cost graphene products aimed at several industrial sectors, including concrete, polymers, Li-ion batteries, and others, which are expected to require large volumes of graphene and, in turn, require large volumes of graphite.

BLACK SWAN GRAPHENE NEW by Black Swan Graphene Inc.

Black Swan Graphene Inc

WIIM

Freeport-McMoRan shares are trading higher after Jefferies upgraded the stock from Hold to Buy and raised its price target from $40 to $48.

Earnings

News

PureCycle Technologies Restricted & Unrestricted Cash Stood At $41.5M As Of Dec 31, 2025

Hayward Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HAYW#NYSE">HAYW</a>) sees FY2025 sales of $1.060 billion-$1.100 billion vs $1.08 billion analyst estimate.

Guidance

HAYW

Hayward Holdings Sees FY2025 Sales $1.060B-$1.100B vs $1.08B Est

Business Outlook
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">First Quarter 2025 Guidance</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">Full-Year 2025 Guidance</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Revenue</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">$130 – 133 million</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">$555 – 570 million</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Year-over-year revenue growth (1)</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">29</td>
<td colspan="1" rowspan="1">%</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">17</td>
<td colspan="1" rowspan="1">%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted EBITDA (2)</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">$28 – 30 million</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">$132 – 138 million</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted EBITDA margin (1)</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">22</td>
<td colspan="1" rowspan="1">%</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">24</td>
<td colspan="1" rowspan="1">%</td>
</tr>
</tbody>
</table>
</figure>

OPRA

Opera Expects Q1 Revenue Of $130M-$133M Vs $121.45M Est, FY25 Revenue Of $555M-$570M Vs $547.10M Est

Hayward Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HAYW#NYSE">HAYW</a>) reported quarterly earnings of $0.27 per share which beat the analyst consensus estimate of $0.24 by 12.5 percent. This is a 35 percent increase over earnings of $0.20 per share from the same period last year. The company reported quarterly sales of $327.07 million which beat the analyst consensus estimate of $302.77 million by 8.03 percent. This is a 17.45 percent increase over sales of $278.47 million the same period last year.

Earnings Beats

Hayward Holdings Q4 Adj EPS $0.27 Beats $0.24 Estimate, Sales $327.07M Beat $302.77M Estimate

Entrada Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRDA#NASDAQ">TRDA</a>) reported quarterly earnings of $0.03 per share which beat the analyst consensus estimate of $(0.67) by 104.48 percent. This is a 110.34 percent increase over losses of $(0.29) per share from the same period last year. The company reported quarterly sales of $37.40 million which beat the analyst consensus estimate of $13.12 million by 185.04 percent. This is a 10.63 percent decrease over sales of $41.85 million the same period last year.

TRDA

Entrada Therapeutics Q4 2024 GAAP EPS $0.03 Beats $(0.67) Estimate, Sales $37.40M Beat $13.12M Estimate

MRNA

Moderna shares are trading lower following reports suggesting officials in the Trump administration are reconsidering $590 million in funding for the company's bird flu vaccine.

The shipment features Pink Kush, the top-selling dried flower strain over the past four years in Canada.

Cannabis

Markets

General

Village Farms International Announced Its First Shipment To New Zealand Through Its Wholly-owned Subsidiary Pure Sunfarms

Company Initiates 2025 Guidance
Kimbell is providing financial and operational guidance ranges for 2025 as follows:
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="3" rowspan="1">Kimbell Royalty</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="3" rowspan="1">Partners LP</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">2025</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Net Production - Mboe/d (6:1)&nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">24.0</td>
<td colspan="1" rowspan="1">-</td>
<td colspan="1" rowspan="1">27.0</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Oil Production - % of Net Production</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">31&nbsp;%</td>
<td colspan="1" rowspan="1">-</td>
<td colspan="1" rowspan="1">35&nbsp;%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Natural Gas Production - % of Net Production</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">46&nbsp;%</td>
<td colspan="1" rowspan="1">-</td>
<td colspan="1" rowspan="1">50&nbsp;%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Natural Gas Liquids Production - % of Net Production</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">17&nbsp;%</td>
<td colspan="1" rowspan="1">-</td>
<td colspan="1" rowspan="1">21&nbsp;%</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Unit Costs ($/boe)</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Marketing and other deductions</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">$1.40</td>
<td colspan="1" rowspan="1">-</td>
<td colspan="1" rowspan="1">$2.20</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Depreciation and depletion expense</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">$13.00</td>
<td colspan="1" rowspan="1">-</td>
<td colspan="1" rowspan="1">$20.00</td>
</tr>
<tr>
<td colspan="1" rowspan="1">G&amp;A</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp; Cash G&amp;A&nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">$2.45</td>
<td colspan="1" rowspan="1">-</td>
<td colspan="1" rowspan="1">$2.65</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp; Non-Cash G&amp;A</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">$1.40</td>
<td colspan="1" rowspan="1">-</td>
<td colspan="1" rowspan="1">$1.80</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Production and ad valorem taxes - % of Oil, Natural Gas and NGL Revenues</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">7.0&nbsp;%</td>
<td colspan="1" rowspan="1">-</td>
<td colspan="1" rowspan="1">9.0&nbsp;%</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Payout Ratio (1)</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">75&nbsp;%</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
</tbody>
</table>
</figure>

Kimbell Royalty Partners 2025 Guidance: Projects Daily Production Between 24,000 Boe/d - 27,000 Boe/d

Wells Fargo initiates coverage on HASI (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HASI#NYSE">HASI</a>) with a Overweight rating and announces Price Target of $33.

Price Target

Initiation

Analyst Ratings

Hannon Armstrong Sustainable Infrastructure Capital

HASI

Wells Fargo Initiates Coverage On HASI with Overweight Rating, Announces Price Target of $33

J.M. Smucker Raises FY25 Adj EPS Guidance From $9.70 - $10.10 To $9.85 - $10.15 Vs. $10.47 Est.

Sotera Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHC#NASDAQ">SHC</a>) is looking for FY2025 Adj EPS of $0.70-$0.76 vs $0.78 analyst estimate. sees sales of $1.144 billion-$1.166 billion vs $1.16 billion analyst estimate.

Sotera Health Sees FY2025 Adj EPS $0.70-$0.76 vs $0.78 Est; Sees net revenues growth outlook of 4.0% - 6.0% YOY  $1.144B-$1.166B vs $1.16B Est

AAON

AAON Says It Believes Nearing End Of Temporary Slowdown Experienced Since Early Last Year; Anticipates Vast Majority Of Total Backlog To Convert In 2025

Warner Bros. Discovery Says Producing New Seasons Of House Of The Dragon, Euphoria, True Detective

On February 26, 2025, Cogent's Board approved a regular quarterly dividend of $1.005 per share payable on March 28, 2025 to shareholders of record on March 13, 2025. This first quarter 2025 regular dividend represents an increase of $0.01 per share, or 1.0%, from the fourth quarter 2024 regular dividend of $0.995 per share and an annual increase of 4.1% from the first quarter 2024 dividend of $0.965 per share.&nbsp;
 &nbsp;
 &nbsp;

Dividends

CCOI

Cogent Communications Board Approved A Quarterly Dividend Per Share Of $1.005 For Q1 Vs $$0.965 A Year Ago

J.M. Smucker Cuts FY25 Sales Growth Guidance From 7.50% - 8.50% To 7.25%

GoHealth (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOCO#NASDAQ">GOCO</a>) reported quarterly earnings of $1.56 per share which beat the analyst consensus estimate of $1.16 by 34.48 percent. This is a 809.09 percent increase over losses of $(0.22) per share from the same period last year. The company reported quarterly sales of $389.13 million which beat the analyst consensus estimate of $324.56 million by 19.89 percent. This is a 40.63 percent increase over sales of $276.70 million the same period last year.

GOCO

GoHealth Q4 EPS $1.56 Beats $1.16 Estimate, Sales $389.13M Beat $324.56M Estimate

Vertex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERX#NASDAQ">VERX</a>) reported quarterly earnings of $0.15 per share which beat the analyst consensus estimate of $0.14 by 7.14 percent. This is a 15.38 percent increase over earnings of $0.13 per share from the same period last year. The company reported quarterly sales of $178.46 million which beat the analyst consensus estimate of $176.90 million by 0.88 percent. This is a 15.20 percent increase over sales of $154.91 million the same period last year.

Comments

Black Swan Graphene Stock News

News

Latest Black Swan Graphene Stock News | OTC:BSWGD | Benzinga

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga